High Tech Pharm (A106190) Stock Overview
Researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
A106190 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
High Tech Pharm Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,020.00 |
| 52 Week High | ₩16,430.00 |
| 52 Week Low | ₩11,130.00 |
| Beta | 0.77 |
| 1 Month Change | -0.33% |
| 3 Month Change | -7.68% |
| 1 Year Change | -14.14% |
| 3 Year Change | 62.43% |
| 5 Year Change | -12.69% |
| Change since IPO | 30.65% |
Recent News & Updates
Investor Optimism Abounds High Tech Pharm Co., Ltd. (KOSDAQ:106190) But Growth Is Lacking
Sep 02
We Think High Tech Pharm (KOSDAQ:106190) Can Stay On Top Of Its Debt
Jun 11Recent updates
Investor Optimism Abounds High Tech Pharm Co., Ltd. (KOSDAQ:106190) But Growth Is Lacking
Sep 02We Think High Tech Pharm (KOSDAQ:106190) Can Stay On Top Of Its Debt
Jun 11A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)
Oct 23Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?
Aug 06Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%
Jul 02There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price Jump
May 09Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?
Apr 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of Debt
Feb 23Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?
Jan 19What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?
Dec 15Shareholder Returns
| A106190 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.0% | 0.4% | 2.5% |
| 1Y | -14.1% | 23.4% | 70.7% |
Return vs Industry: A106190 underperformed the KR Pharmaceuticals industry which returned 23.4% over the past year.
Return vs Market: A106190 underperformed the KR Market which returned 70.7% over the past year.
Price Volatility
| A106190 volatility | |
|---|---|
| A106190 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A106190 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A106190's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Jeong-Soo Kim | www.htpharm.com |
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.
High Tech Pharm Co., Ltd. Fundamentals Summary
| A106190 fundamental statistics | |
|---|---|
| Market cap | ₩127.81b |
| Earnings (TTM) | ₩11.98b |
| Revenue (TTM) | ₩75.60b |
Is A106190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A106190 income statement (TTM) | |
|---|---|
| Revenue | ₩75.60b |
| Cost of Revenue | ₩59.24b |
| Gross Profit | ₩16.36b |
| Other Expenses | ₩4.38b |
| Earnings | ₩11.98b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.13k |
| Gross Margin | 21.65% |
| Net Profit Margin | 15.85% |
| Debt/Equity Ratio | 0% |
How did A106190 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 13:19 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
High Tech Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.